Time to culture conversion among LFU and non-LFU groups using Kaplan-Meier’s analysis.

<p>Time to culture conversion among LFU and non-LFU groups using Kaplan-Meier’s analysis.</p

Time to LFU following initiation of MDR-TB treatment at the Drug Resistant TB Site at Vadodara, Gujarat, India using Kaplan-Meier’s analysis.

<p>Time to LFU following initiation of MDR-TB treatment at the Drug Resistant TB Site at Vadodara, Gujarat, India using Kaplan-Meier’s analysis.</p

MDR-TB treatment outcomes of patients at at Drug Resistant TB Centre in Vadodara, Gujarat, India.

<p>*Transferred out and not recorded 10</p><p>^#Not recorded 2</p><p>MDR-TB treatment outcomes of patients at at Drug Resistant TB Centre in Vadodara, Gujarat, India.</p

Baseline characteristics of MDR-TB patients on treatment, LFU and non-LFU patients at Drug Resistant TB Centre in Vadodara, Gujarat, India.

<p>*Number varies according to data available from records IQR-Inter Quartile Range; DOT-Direct Observed Treatment; IP- Intensive Phase; CP-Continuation Phase.</p><p>Baseline characteristics of MDR-TB patients on treatment, LFU and non-LFU patients at Drug Resistant TB Centre in Vadodara, Gujarat, India.</p

Direct Observation (DO) or non-DO as reported by patients, DOT-providers and MSF staff.

<p>(A) DR-TB patients following Strict-DO, DO or not following DO during their treatment. (B) DR-TB patients following DO or not following DO during most recent week of their treatment.</p

Demographic and clinical characteristics of drug-resistant tuberculosis patients with linezolid-associated optic neuropathy, Mumbai, January 2013-April 2016.

<p>Demographic and clinical characteristics of drug-resistant tuberculosis patients with linezolid-associated optic neuropathy, Mumbai, January 2013-April 2016.</p

Demographic and clinical characteristics of drug-resistant tuberculosis patients on Linezolid-containing regimen in Mumbai, India, January 2013-April 2016.

<p>Demographic and clinical characteristics of drug-resistant tuberculosis patients on Linezolid-containing regimen in Mumbai, India, January 2013-April 2016.</p

Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India - Fig 2

<p>Perimetric Findings of Case 2; A) Right eye at diagnosis showing centrocecal scotomas with an associated bitemporal central scotoma and B) Right eye at day 45 showing resolution. Similar findings are seen in the Left eye at diagnosis (C) and at day 45 (D).</p

Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India - Fig 3

<p>Perimetric Findings of Case 4; A) Right eye at diagnosis showing centrocecal scotomas with an associated bitemporal central scotoma and B) Right eye at day 38 showing worsening. Similar findings are seen in the Left eye at diagnosis (C) and at day 38 (D).</p

Thematic analysis for “Reasons for loss to follow up.

<p>Thematic analysis for “Reasons for loss to follow up.</p